The Bcl-2 inhibitor Venetoclax (ABT-199) was recently approved for the treatment of chronic lymphocytic leukemia and is currently tested in several ongoing clinical trials to treat multiple hematological malignancies [41]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.